Skip to main content
. 2023 Mar 3;13:1097911. doi: 10.3389/fonc.2023.1097911

Table 2.

Curative effect evaluation.

Clinical efficacy Fruquintinib group (49), n. (%) Regorafenib group (49), n. (%) p-value
Overall response 0.231
Complete response 0 0
Partial response 3 (6.1) 1 (2.0)
Stable disease 29 (59.2) 25 (52.1)
Progressive disease 17 (34.7) 22 (45.8)
Objective response rate 3 (6.1) 1 (2.0) 0.610
Disease control rate 32 (65.3) 26 (54.2) 0.218